Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Memory tricks tested to sharpen aging brains

NCT ID NCT07479914

Symptom relief Sponsor: University of Milano Bicocca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if learning memory techniques (like mnemonics) can improve thinking and memory in adults over 50 who have mild memory concerns. 80 participants will either take memory training or just get information. The goal is to see if training helps and if benefits last up to 9 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Nov 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Subjective Cognitive Decline (SCD) according to Jessen et al., 2014 criteria * Evaluation at the Brain Health Service (BHS) of Monza * Prior brain MRI performed at Fondazione IRCCS San Gerardo dei Tintori * Prior blood sampling for measurement of biomarkers of cerebral amyloidosis * Age \> 50 years * Adequate digital literacy (ability to access websites and participate in video calls) * Ability and willingness to provide written informed consent before study participation Exclusion Criteria: * Severe visual and/or hearing impairment interfering with participation * Inability to participate in online training activities or attend in-person group sessions * Enrollment in another interventional study with an expected effect on cognition * Refusal or withdrawal of consent to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease subjective cognitive decline

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease Cognitive enhancement Subjective cognitive decline (SCD)

Contacts and locations

Locations

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza, Lombardy, 20900, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.